Worldwide Shipping✦For research purposes only.✦We guarantee quality and assurance.✦Worldwide Shipping✦For research purposes only.✦We guarantee quality and assurance.✦Worldwide Shipping✦For research purposes only.✦We guarantee quality and assurance.✦
MedTruva
BODYMAP™ About Sign in
Medtruva RETA-GLP3 retatrutide 30mg research peptide vial
R3TA-3GLP - Image 2
Medtruva RETA-GLP3 retatrutide 50mg research peptide vial
Three vials of Medtruva RETA-GLP3 retatrutide 40mg research peptide, 1-year supply

R3TA-3GLP

Price range: $180.00 through $960.00

R3tatrutide (LY3437943) is an investigational triple receptor agonist targeting GIPR, GLP-1R, and GCGR. Available in 30 mg, 40 mg, and 50 mg research formats; strictly for laboratory research and not for human or veterinary use.

Research Sharing Package: 10 x 40 mg vials for $960. That’s just $96 per vial — an amazing deal.
Buy 4, get 6 free: 10 vials x 40 mg = 400 mg total, $960 ÷ 10 = $96.00 per vial (vs. $240 per single 40 mg vial).

US ordering opens soon. Researchers in Dubai can order now by switching to the UAE store.

98.99%+ PurityResearch GradeCOA VerifiedThird-Party Tested
View the certificate of analysis for this compound →

Not available to order yet — coming soon.

American based – premium qualityTrusted brand – customers choice100% tested – premium qualityCOA certified – lab tested, always trustedBest pricing – always competitive

The Purity Guarantee

Verified ≥99% by HPLC & mass spectrometry, third-party tested, with a lot-matched Certificate of Analysis on every vial.

  • Certificate of Analysis available for every lot
  • ≥99% purity, HPLC & mass-spec verified
  • Secure checkout · Free shipping on orders $300+
SKU: MT-RETA Category:

Description

Scientific overview

R3tatrutide (LY3437943) is an investigational, single-molecule peptide agonist engineered to activate three nutrient-responsive receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). These class B G protein-coupled receptors participate in the regulation of pancreatic hormone secretion, appetite signaling, energy balance, and substrate metabolism.

Simultaneous GIPR, GLP-1R, and GCGR agonism is being studied as a strategy to integrate incretin signaling with glucagon-receptor-mediated effects on hepatic metabolism and energy expenditure. R3tatrutide has undergone Phase 2 and Phase 3 clinical investigation across obesity and related cardiometabolic conditions; it remains investigational and is not approved for public use as of September 2026.

Research characteristics

  • Molecular class: synthetic, long-acting peptide receptor agonist
  • Primary targets: GIPR, GLP-1R, and GCGR
  • Research focus: nutrient signaling, glucose and lipid metabolism, energy homeostasis, and body-composition biology
  • Available research formats: 30 mg, 40 mg, and 50 mg

Research-use notice: Supplied for laboratory research only. Not for human or veterinary use, diagnosis, treatment, or consumption. No medical or therapeutic claims are made.

Certificate of Analysis

Every Medtruva lot ships with an independent, third-party certificate of analysis covering identity and purity. The certificate for each lot is published here and searchable by lot number.

Verified
CompoundR3TA-3GLP · MT-RETA
Lot numberMETSABD-S26-5789 (40 mg vial)
Analytical methodsHPLC
Purity99.89% (HPLC) · 40 mg vial
Testing laboratoryMiddle East Testing Services (METS), Abu Dhabi
Report date2026-10-08
Download certificate (PDF) Look up a lot number →

For laboratory research only. Certificates describe the analytical results of a specific lot and are not a statement of suitability for any use.

Additional information

Vial Size

30 mg, 40 mg, 50 mg, 1 Year Supply of Research (3 x 40 mg), Research Sharing Package (10 x 40 mg)

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Related products